rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Nagasaki University Graduate School of Biomedical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Baricitinib group; 1.The patients who fulfill 2010 ACR/EULAR criteria of Rheumatoid arthritis. 2.The patients who are indicated of baricitinib treatment. 3.The disease activity score is more 3.2. 4.The patient aged >20 years when signing his/her informed consent. Control group 1.The patients who fulfill 2010 ACR/EULAR criteria of Rheumatoid arthritis. 2.The patients who are treated by conventional synthetic DMARDs over the 3 months. 3.The disease activity score is more 3.2. 4.The patient aged >20 years when signing his/her informed consent.
Exclusion criteria
Exclusion criteria: 1.Pregnant patients 2.The patients who cannot rest the extremities during taking HR-pQCT. 3.The patients who is treated with prednisone >10mg 4.The patients who are taking intraarticular corticosteroid injection into evaluation joints within 6 months before enrollment. 5.The patients who are complicated with other disease which can affect evaluation joint. 6.In the opinion of the investigator, the patients who is not suitable for this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of volume of bone erosion in RA treated by baricitinib and csDMARDs which detected by HR-pQCT from baseline to 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To evaluate the change of bone microarchitecture using HR-pQCT from baseline to 12 months. 2. To investigate the relation between HR-pQCT and finding of other modality such as musculoskeletal ultrasonography. 3, To investigate the relation between HR-pQCT and biomarkes measured by multiplex bead assays. | — |
Countries
Japan
Contacts
Public ContactNaoki Iwamoto
Nagasaki University Graduate School of Biomedical Sciences Department of Immunology and Reumatology, Unit of Advanced Preventive Medical Sciences
Outcome results
None listed